Systemic Anti cancer treatment Flashcards

1
Q

What is chemotherapy?

A
  • COMPOUND TARGETING DNA, RNA & PROTEINS - AIM IS TO FORCE CELLS INTO APOPTOSIS! - IT IS NON -SPECIFIC TO CANCER CELLS
    *ALL RAPIDLY DIVIDING CELLS ARE AFFECTED *
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How is chemotherapy delivered?

A
  • IV & ORAL PREPARATIONS
  • FREQUENCY OF ADMINISTRATION= CYCLES
  • CYCLES DETERMINED BY PHARMACOKINETICS
  • COMBINATION CHEMO - increased EFFICACY
  • NEOADJUVANT (given before surgery)/ ADJUVANT (reduce risk of cancer returning)/ DISEASE CONTROL
    PALLIATIVE(control disease for as long as possible)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the 3 main types of chemotherapy?

A
  • Alkylating agents and platinum drugs - form DNA adducts
    blocking DNA replication (all phases of cell cycle)
    certain alkylating agents have ability to create cross links (changing structure of the DNA helix) and can act in all phases of cell cycle
  • Antimetabolites - structurally mimic essential molecules
    required for cell division (S phase of cell cycle)
    These may be incorporated into new nuclear material or bind irreversibly with vital enzymes for cell division
  • Organic drugs - vinca alkaloids / taxanes / anthracyclines
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Give examples of organic drugs?

A
  • Vinca alkaloids - bind to tubulin and prevent
    microtubule assembly - which is essential for metaphase and mitosis
  • Taxanes - bins to beta tubulin subunit inhibiting
    depolymerisation and disrupting mitotic spindle
  • Anthracyclines - microbial antibiotic targets
    topoisomerase II (enzyme that releases torsional stress during the DNA replication)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Side effects of chemotherapy?

A

nausea and vomiting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Give examples of personalised systemic therapies?

A
  • Hormonal Therapies - Anti - oestrogen, Aromatase
    inhibitors
  • Targeted Therapies - EGFR, VEGF, CDK 4/6
  • Immunotherapy - PD 1, PD -L1, CTLA - 4
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which hormones are linked to breast cancer?

A

Oestrogens (estradiol/esterone) play major role

Oestrogens promote cell proliferation within the breast tissue (higher rate of
cell division = more chances for mutations)

Prolonged exposure to oestrogen- increased RISK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are breast cancer drugs?

A

Breast cancer drugs
Anti- oestrogen = Tamoxifen: Binds to the
oestrogen receptor and blocking oestrogen induced proliferation of cells

Aromatase inhibitors = Letrozole: Block
conversion to androgens to oestrogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe how EGF works?

A

EGF binds to the tyrosine kinase receptor on cell membrane and this leads to receptor dimerization and autophosphorylation.
Following this there is activation of intracellular transducers including RAS pathway and transcription.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What have tyrosine kinase inhibitors been developed for?

A

to target tumours that express the EGF receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What stem cells is the immune system derived from?

A

haematopoietic stem cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What do B cells do?

A

produce tumour specific antibodies- induce cell lysis and ultimately death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What do T cells do?

A

helper T cell vs cytotoxic t cells - kill cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are immune checkpoints for?

A

to ensure that self tolerance is maintained

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are immune checkpoints activated by?

A

Activated by receptor ligand
binding (PD-1 to PD-L1)
(CTLA-4 to B7)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What do immune checkpoint inhibitors do?

A

(PD1 PDL1 AND CTLA-4)
removal of the brakes of the
immune system allowing
increased T cell activity

17
Q

What are cyclic kinases and cyclin dependent kinases responsible for?

A

movement of cells through cell cycle

18
Q

What does cyclin D along with CDK4/6 responsible for?

A

helps to move cells from the G0 resting phase into G1 to begin growth

production of cyclin d regulates cyclin e - which controls passage into s phase

19
Q

Immunotherapy side effects?

A
  • Colitis - most common - 30% develop diarrhoea of any grade and
    10% have severe grade 3-4 in dual IO.10
  • Pneumonitis - more common in PD-L1 treatment reference 11
  • Hypophysitis/ Thyroid dysfunction/ Diabetes - 5-10% develop
    endocrine adverse events reference 12
  • Hepatitis - occurs <5% 11
  • Dermatitis - most frequent toxicity for PD-L1 and CTLA-4 11
  • Nephritis - <1 % 11
  • Neurological <0.2% 11
20
Q

What are side effects of EGF receptor inhibitors?

A

not entirely specific and still cause disruption to normal cells.
Resulting in side effects such as diarrhoea, dry skin, rash , hypertension and deranged liver function.

21
Q

What does the inhibitor ,palbociclib, do?

A

block the progression of cells through cell cycle in metastatic breast cancer

22
Q

What are the descendents of stem cells called?

A

progenitor cells

23
Q

What are progenitor cells divided into?

A

myeloid or lymphoid

24
Q

Which cells respond early?

A

neutrophils and NK cells

25
Q

What cells respond later?

A

B and T cells -adaptive immune response

26
Q

How do PD-1 inhibitors drive killing of cancer cells by t cells?

A

PD-1 found on T cells binds to another protein called PD-L1 helping to keep T cells from killing other cells including cancer cells.
PD-1 inhibitors block binding to PD-L1 and this means the brakes on immune system are released and t cells can kill cancer cells.

27
Q

What is pembrolizumab? (KEYTRUDA)

A

selective humanised IgG4 monoclonal antibody targeted at the PD-1 checkpoint

blocks PD-1 receptors from binding to immune dampening PD-1 and PD-2 ligands in the tumour

28
Q
A